BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 15637459)

  • 21. Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
    Ay SA; Cakar M; Karaman M; Balta S; Demirkol S; Unlu M; Kurt O; Altun B; Akhan M; Arslan E; Koc B; Bulucu F
    Ren Fail; 2013; 35(3):357-60. PubMed ID: 23297711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K; Dohi Y; Nakazawa A; Sugiura T; Yamashita S; Sato K; Kimura G
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
    Yamada H; Suga N; Maeda K; Kimura Y; Miura N; Futenma A; Imai H
    Arzneimittelforschung; 2010; 60(2):64-70. PubMed ID: 20329653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.
    Sueta D; Nakamura T; Dong YF; Kataoka K; Koibuchi N; Yamamoto E; Toyama K; Yasuda O; Ogawa H; Kim-Mitsuyama S
    Am J Hypertens; 2012 Jun; 25(6):704-10. PubMed ID: 22421905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
    Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
    Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R; Mugellini A; Derosa G;
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
    Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
    J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical implications from the results of the CASE-J extension].
    Yasuno S; Fujimoto A; Ueshima K
    Nihon Rinsho; 2012 Mar; 70(3):519-27. PubMed ID: 22514936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term renoprotective effect of candesartan in renal transplant patients.
    Ishii T; Yasuda M; Itami Y; Hayashi T; Uemura H; Nose K; Nishioka T
    Transplant Proc; 2012 Apr; 44(3):638-41. PubMed ID: 22483458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate.
    Nakagawa N; Fujino T; Kabara M; Matsuki M; Chinda J; Kikuchi K; Hasebe N;
    Hypertens Res; 2011 Oct; 34(10):1121-6. PubMed ID: 21796123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial.
    Halimi JM; Giraudeau B; Buchler M; Al-Najjar A; Etienne I; Laouad I; Bruyère F; Lebranchu Y
    Clin Transplant; 2007; 21(2):277-84. PubMed ID: 17425758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
    Koyanagi R; Hagiwara N; Yamaguchi J; Kawada-Watanabe E; Haruta S; Takagi A; Ogawa H;
    J Cardiol; 2013 Oct; 62(4):217-23. PubMed ID: 23778009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.